Reducing treatment before stopping for chronic myeloid leukemia
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This study looks at whether people with chronic myeloid leukemia (CML) can safely lower their dose of targeted therapy before completely stopping it. It aims to see if a gradual reduction helps maintain long-term remission without the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had CML in the chronic phase (not the advanced phase).
- You have been on your current CML treatment for at least 3 years (or 5 years if on a first-generation drug).
- You have had a deep molecular response (very low or undetectable levels of the BCR-ABL gene) for more than 2 years, with at least 4 tests showing this.
- You have not had a stem cell transplant before.
- You do not have HIV, hepatitis C, syphilis, or any other condition that weakens the immune system.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at stopping TKI treatment (a type of targeted therapy for CML) to see if you can stay in remission without medication. It is for people with CML in chronic phase who are either newly diagnosed or on a TKI but not achieving optimal results or not tolerating the drug.
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
This trial tests if people with chronic myeloid leukemia (CML) who have already tried to stop their TKI medication once and lost a deep remission, can safely stop their TKI again after taking a newer drug called asciminib. The goal is to stay in remission (no detectable leukemia) without needing daily medication.
This trial tests if a short course of pioglitazone (a diabetes drug) before stopping your TKI therapy can help you stay in remission longer. It is for people with chronic myeloid leukemia (CML) who have already lost their remission after a first or later attempt to stop TKI treatment.
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
This follow-up study looks at people with chronic myeloid leukemia (CML) who have been in deep remission and may be able to stay off treatment. It checks how long remission lasts and how their leukemia tests behave over time.
Hear when a new Chronic Myeloid Leukemia in Chronic Phase trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.